PROGRAM BOOK
Hosted by
Supported by CONTENTS
Welcome Message 02
Organization of ASGO 03
Organizing Committee of ASGO 2019 04
ASGO 2019 Information 06
Speaker Information 08
Poster Presentation (Display) Schedule 09
Become a Member of ASGO 10
Program at a Glance 11
Scientific Program 15
Thursday, October 10 Friday, October 11 Saturday, October 12
Poster 45
Poster Discussion Poster Display
Tour Information 72
Exhibition 74
Floor plan 76 Welcome Message Organization of ASGO
Dear Colleagues and Friends, [President] Hee-Sug Ryu (Korea)
Welcome to the 6th Biennial Meeting of Asian Society of Gynecologic [Secretary General] Suk-Joon Chang (Korea) Oncology (ASGO 2019) in Korea! [Treasurer] Jae-Weon Kim (Korea)
On behalf of the Organizing Committee, we cordially invite you to [JGO Editor-in-Chief] Jae-Weon Kim (Korea) ASGO 2019 in Songdo, Incheon, Korea from October 10 to 12. [President-Elect] Daisuke Aoki (Japan) Since 2008, when ASGO was officially founded by a group of [Immediate Past President] Ikuo Konishi (Japan) gynecologic oncologists in Asia, ASGO has rapidly grown up through hosting five successful biennial meetings and workshops both in [Nominating Committee] Shingo Fujii (Japan) Korea and Japan. For the last 11 years, ASGO have made utmost effort Soon-Beom Kang (Korea) to share various studies, educational environment and to promote Toshiharu Kamura (Japan) women’s health. Indeed, the Organizing Committee of ASGO 2019 has Joo-Hyun Nam (Korea) prepared for the wide range of scientific programs and pleasant social activity programs as well. The 6th Biennial Meeting is expected to be [Council Members] Andri Andrijono (Indonesia) the center of cutting-edge research and education on Gynecologic Duk-Soo Bae (Korea) Oncology as well as hope for gynecologic cancer patients in Asia. Chunling Chen (China) Neerja Bhatla (India) We believe all participants will truly enjoy their time and have an Efrén Domingo (Philippines) unforgettable memory in ASGO 2019. Extending a warm welcome to Seung Cheol Kim (Korea) th all of you here, we really look forward to meeting you at the 6 Biennial Suresh Kumarasamy (Malaysia) Meeting of ASGO. Hextan Ngan (Hong Kong) David Tan (Singapore) Sincerely yours, Nobuo Yaegashi (Japan) Kung-Liahng Wang (Taiwan) Sarikapan Wilailak (Thailand) Rongyu Zang (China)
Hee-Sug Ryu, M.D., Ph.D. ASGO President
Seung Cheol Kim, M.D., Ph.D. ASGO 2019 Organizing Committee Chair
02 03 [Social Program Committee] Organizing Committee of Chair Jae-Kwan Lee (Korea University) ASGO 2019 Vice Chair Young-Han Park (Hallym University) Vice Chair Won Deok Joo (CHA University) [President of ASGO] Hee-Sug Ryu (Ajou University) [Advertising Committee] Chair Yoon Soon Lee (Kyungpook National University) [Chair] Vice Chair Ki Hyung Kim (Pusan National University) Seung Cheol Kim (Ewha Womans University) Vice Chair Kwang Beom Lee (Gacheon University)
[Secretary General] [Exhibition Committee] Dong Hoon Suh (Seoul National University) Chair Seok Mo Kim (Chonnam National University) Vice Chair Seob Jeon (Soonchunhyang University) [Advisors] Vice Chair Seung-Su Han (Chung-Ang University) Soon-Beom Kang (Seoul National University) Joo-Hyun Nam (University of Ulsan) [Publication Committee] Duk-Soo Bae (Sungkyunkwan University) Chair Byoung-Gie Kim (Sungkyunkwan University) Young Tak Kim (University of Ulsan) Vice Chair Ju-won Roh (Dongguk University) Vice Chair Sokbom Kang (National Cancer Center) [Scientific Program Committee] Chair Jae-Weon Kim (Seoul National University) Vice Chair Jong Min Lee (Kyung Hee University) Vice Chair Rongyu Zang (Fudan University)
[Finance Committee] Chair Yong Man Kim (University of Ulsan) Vice Chair Tae Jin Kim (Dankook University) Vice Chair Seok Ju Seong (CHA University)
[International Relations Committee] Chair Young Tae Kim (Yonsei University) Vice Chair Sang Young Ryu (Korea Cancer Center) Vice Chair Chulmin Lee (Inje University)
[Planning Committee] Chair Soo Young Hur (Catholic University) Vice Chair Joong Sub Choi (Hanyang University) Vice Chair Sung Yob Kim (Jeju National University)
04 05 Preview Room ASGO 2019 Information All speakers are requested to visit the Preview Room (Room 208) to check your presentation file at least 3 hours before your session starts Meeting Venue to ensure your file appears properly. Songdo Convensia, Incheon, Korea - Place: Room 208 (2F), Songdo Convensia - Address: 123 Central Street, Yeonsu-gu, Incheon 21998 Korea - Preview Room Opening Hours: - TEL: +82-32-210-1114 / Website: http://www.songdoconvensia.com Thursday, October 10 07:00 – 18:30 Friday, October 11 07:00 – 18:30 Registration Saturday, October 12 07:00 – 15:00 - Place: Lobby (2F), Songdo Convensia - Registration Desk Opening Hours: Certificate of Attendance Thursday, October 10 07:30 – 18:30 Friday, October 11 07:30 – 18:30 The certificate of attendance is enclosed in the advertisement book. You can find it at the end of the advertisement book. Saturday, October 12 07:30 – 15:00
- Registration Fee: WIFI On-Site Registration Category (2019. 10. 10 - 10. 12) Free WIFI will be available in selected meeting area, including the exhibition area and the session hall. Gynecology Oncologists, Other Department Physician 500USD - User name: convensia Staffs of the Pharmaceutical Company - Password: asgo2019 Fellow/ Trainee 400USD
Nurse [ONLY 10.10] 50USD Exhibition - Place: Grand Ballroom C, Lobby (2F), Songdo Convensia Nurse / Researcher / 300USD Graduate Student / Student - Exhibition Opening Hours:
Accompanying Person Thursday, October 10 09:00 – 18:00 100USD [Banquet only (10.10/ 10.11)] Friday, October 11 09:00 – 18:00 Accompanying Person Saturday, October 12 09:00 – 18:00 300USD [Tour (10.10) + Banquet (10.10/ 10.11)] Smoking Policy Mobile APP The ASGO 2019 and the concomitant Exhibition have been designated Install the ASGO 2019 interactive mobile App to your mobile phones as no-smoking events throughout the entire venue, including all and tablets to access all the meeting information. meeting halls, functions, registration and catering areas. All the - Session overview, speakers and exhibitors participants are kindly required to respect the no-smoking policy. - Browse abstracts and presentation files - Create your personal schedule for the event, including bookmarking the sessions you are interested in Download the ASGO 2019 App now to enhance your meeting experience! (available on the App Store or Google Play).
06 07 Speaker Information Poster Presentation (Display)
Speaker Information Schedule - Preview Room Opening Hours: Poster Presentation (Display) Schedule Thursday, October 10 07:00 – 18:30 Friday, October 11 07:00 – 18:30 Set up Thursday, October 10 09:00 - 18:00
Saturday, October 12 07:00 – 15:00 Thursday, October 10 09:00 - 18:00
All speakers and oral abstract presenters should deliver and check their Display Friday, October 11 09:00 - 18:00 presentation files at the Preview Room (Room 208) at least 3 hours Saturday, October 12 09:00 – 14:00 before the start of the session. Speakers are kindly required to finish their presentation within the given time limits, including Q&A time. Removal Saturday, October 12 14:00 -15:30
Chairperson Poster Board Number If you are a chairperson, please be in your session rooms 10 minutes Please refer to the page 46 and mobile App to locate your presentation prior to start of the session. For organizational purposes, chairpersons Number. Kindly use this presentation Number only. must keep strictly to the time allocated in the program. Poster Overview We invite all ASGO 2019 attendees to view posters during the breaks as indicated in the Scientific Program. Poster Viewing Presentations have no specific presentation time. The presenters may stand by the Poster in order to present their Poster during breaks.
Removal You may remove your poster on Saturday, October 12, from 14:00 to 15:30. Meeting staff will remove all posters left on the boards on Saturday, October 12 at 15:30. Please note that the organizers do not take any responsibility for returning uncollected material to the authors.
08 09 Become a Member of ASGO Program at a Glance
The Asian Society of Gynecologic Oncology (ASGO) is the leading Thursday, October 10 Asian organization with professionals from over 10 countries involved Thursday, October 10 in prevention, treatment, care and research of gynecologic cancers. GBR A GBR B 204-205 206-207 GBR C & Lobby ASGO membership provides the unique opportunity to access to precious resources from previous meetings, establish personal and 08:30 29th KGOG professional relationships, and participate in all ASGO meetings with Symposium 09:00 & discounted registration fee. 13th Korea- th th 09:30 25 Annual 25 Annual Shingo Fujii Japan Symposium of Symposium of Medical Gynecologic KSGO 2019 KSGO 2019 Academy Benefits 10:00 Oncology [Nursing Group Joint Session] Meeting Access to members-only page 10:30 You can find ASGO meeting resources such as abstracts, 08:20-12:15 08:00-12:15 08:00-12:30 (*Satellite posters, and congress videos. 11:00 Symposium - Roche Korea) 11:30 07:50-12:15 Discounted registration fee for all ASGO meetings 12:00 Enjoy reduced registration fees to get opportunity to Break 12:15-12:35 12:30 communicate with professionals in our meetings. Special Symposium 1 Sponsored by Astrazeneca Break 13:00 * Luncheon 12:35-13:25 Exhibition 12:30-13:45 & Opening Ceremony Poster 13:30 13:25-13:45 Right to participation in vote Display You will have right to submit nominations and vote for Plenary 1 Shingo Fujii 14:00 Medical President Invited Lectures ASGO officers and council members, and be elected and Academy 13:45-14:45 serve on ASGO committees as well. 14:30 13:45-14:55 Break 14:45-15:05 15:00 Sympo 1 Edu 1 Oral 1
Rare Radiation 15:30 Gynecologic Cervical Cancer Gynecologic Screening/CIN Cancers: Oncology What is new? 16:00 15:05-16:35 15:05-16:35 15:05-16:35 16:30 Break 16:35-16:55
Sympo 2 Edu 2 Oral 2 17:00 Cervical Cancer Gyne-Oncologic Endometrial Screening in Pathology Hyperplasia/ 17:30 Asia Cancer 16:55-18:25 16:55-18:25 16:55-18:15 18:00
VISIT www.asiansgo.org 18:30 to become a member of the ASGO! 19:00 Welcome Reception 19:30 19:00-21:00
10 11 Friday, October 11 Saturday, October 12
Friday, October 11 Saturday, October 12
GBR A GBR B 205 206-207 GBR C & Lobby GBR A 204-205 206-207 GBR C & Lobby
08:30 Edu 3 08:30 Poster Discussion Sympo 3 Sympo 4 Special 3 08:30-08:50 Oral 5 ERAS Revised FIGO International Endometrial Edu 5 09:00 Stage of 08:30-09:05 09:00 Research Cancer Cervix Cancer & Collaboration Uterine and TR & Hereditary Update Special 1 Related Issues through GCIG Cervical Cancer Molecular Dissection 09:30 of Ovarian Clear Cell 09:30 Surgery 08:30-10:00 08:30-10:00 Carcinoma 08:30-10:00 08:30-10:00 09:10-10:00 09:00-10:00
10:00 Break 10:00-10:20 10:00 Break 10:00-10:20 Special 4 10:30 10:30 Clinical Trial in Asia: Can We Film 1A Oral 6 Plenary 2 Make a Quantum Jump? Cervical Cancer & 10:20-11:05 10:20-11:05 GTN Treatment 11:00 Surgical Issues in 11:00 Gynecologic Oncology Field Edu 6 10:20-11:30 Training Session for Young Film 1B Exhibition 11:30 11:30 Investigator and Research 11:05-11:50 & 10:20-12:10 Nurse Poster 11:10-12:00 Display 12:00 12:00 Break 12:00-12:10 Break 12:10-12:20 Special Symposium 3 12:30 Special Symposium 2 12:30 Sponsored by Takeda Sponsored by Roche * Luncheon 12:10-13:00 * Luncheon12:20-13:10 Exhibition 13:00 & 13:00 Sympo 7 Edu 7 Special 5 Plenary 3 Poster Fertility Preservation Imaging in Ovarian From Good Research Display 13:30 13:30 Upfront Cancer Practice to Good Publication PAPRi, Immuno-oncology 13:00-14:00 13:00-14:00 13:00-14:00 and Beyond 14:00 14:00 Sympo 8 Edu 8 Oral 7 13:10-14:40 Chemotherapy and Ovarian Cancer Medical Treatment in Related Supportive Surgery Ovarian Cancer 14:30 14:30 Care Break 14:40-15:00 14:05-15:05 14:05-15:05 14:05-15:05
15:00 Sympo 5 Sympo 6 Oral 3 15:00 Closing Ceremony Ovarian 15:05-15:20 Hereditary MIS in Cancer 15:30 Breast and gynecologic Roundtable TR in Ovarian 15:30 Ovarian Cancer cancer Session of Cancer in Asia management Chinese 16:00 Gynecologic 16:00 15:00-16:30 15:00-16:30 Oncologists 15:00-16:30
16:30 Break 16:30-16:50 15:00-17:00 Break 16:30-16:50 16:30
17:00 Edu 4 Special 2 Oral 4 17:00 ASGO-AOGIN Issues in Surgical and Joint Session: How Surgical Molecular to Collaborate to 17:30 Eradicate Cervical Treatment 17:30 Tumor Board Cancer in Asia- 16:50-18:10 Pacific Region 18:00 16:50-18:20 16:50-18:20 18:00
18:30 18:30
19:00 Banquet 19:00 18:45-21:00
19:30 PBR A, B 19:30
12 13 NOTE
SCIENTIFIC PROGRAM
Thursday, October 10 16
14 Thursday, October 10 12:35-13:45 Luncheon & Opening Ceremony
08:00-14:55 [Shingo Fujii Medical Academy] Room 204, 205 13:45-14:20 Reduced-port laparoscopic nerve sparing (type C1) radical Organizer: Shingo Fujii (Kyoto University, Japan) hysterectomy Co-organizer: Joo-Hyun Nam (University of Ulsan, Korea) Dae-Yeon Kim (University of Ulsan, Korea) Kung-Liahng Wang (Taitung Mackay Memorial Hospital, Taiwan) 14:20-14:55 A modified technique for nerve-sparing radical hysterectomy Commentators: Young Tak Kim (University of Ulsan, Korea) Kittipat Charoenkwan (Chiang Mai University, Thailand) Sang-Yoon Park (National Cancer Center, Korea) Yoon Soon Lee (Kyungpook National University Chilgok Hospital, Korea) Noriaki Sakuragi (Hokkaido University, Japan)
THURSDAY Hidetaka Katabuchi (Kumamoto University, Japan) Mikio Mikami (Tokai University, Japan) Tomoyasu Kato (National Cancer Center Hospital, Japan) Masaki Mandai (Kyoto University, Japan) THURSDAY
08:00-08:05 Introduction of Shingo Fujii Soon-Beom Kang (Seoul National University, Korea)
08:05-08:40 Robot-assisted laparoscopic nerve sparing radical hysterectomy and bilateral pelvic lymphadenectomy for early cervical cancer Wu-Chou Lin (China Medical University Hospital, Taiwan)
08:40-09:15 Surgical anatomy of para-vesico vaginal space Rongyu Zang (Zhongshan Hospital, Fudan University, China)
09:15-09:50 Example video for discussion
09:50-10:25 Anatomy of the posterior–leaf of the vesicouterine ligament Tetsu Asai & Mikio Mikami (Shin-Yurigaoka General Hospital, Japan)
10:25-10:45 Break
10:45-11:20 Preservation of rectal branches of Inferior hypogastric plexus during resection of rectovaginal ligament Yoon Soon Lee (Kyungpook National University Chilgok Hospital, Korea)
11:20-11:55 Nerve-sparing radical hysterectomy Yasushi Kotani (Kindai University Hospital, Japan)
11:55-12:30 Anatomy and procedure performed safely of the vesicouterine ligament Kentaro Sekiyama (Kitano Hospital, Japan)
12:30-12:35 Break
16 17 12:35-12:55 [Special Symposium 1] GBR A, B Sponsored by Astrazeneca Chair: Jong-Hyeok Kim (University of Ulsan, Korea)
12:35-12:55 Evolving of BRCA mutated ovarian cancer treatment: study 19 Richard Penson (Massachusetts General Hospital, USA) THURSDAY
18 15:45-16:05 The role of brachytherapy in the treatment of cervical cancer 13:25-13:45 [Opening Ceremony] GBR A, B Chomporn Sitathanee (Mahidol University, Thailand) Opening remarks: Seung Cheol Kim (Ewha Womans University, Korea) 16:05-16:25 MRI-guided brachytherapy in cervical cancer in Korea Congratulatory remarks: Hee-Sug Ryu (Ajou University, Korea) Yeon Joo Kim (National Cancer Center, Korea)
13:45-14:45 [Plenary Session 1] President Invited Lectures GBR A, B 16:25-16:35 Discussion Chair: Hee-Sug Ryu (Ajou University, Korea) Ikuo Konishi (National Hospital Organization Kyoto 15:05-16:35 [Oral 1] Cervical Cancer Screening/CIN Room 206, 207 Medical Center, Japan) Chair: Jae Yun Song (Korea University, Korea) Tae Joong Kim (Samsung Medical Center, Korea) 13:45-14:15 Toward precision medicine: evolution of global distributed research network in Korea THURSDAY 15:05-15:15 Identification of key genes and microRNAs in cervical cancer Rae-Woong Park (Ajou University, Korea) progression by integrated bioinformatics analysis Yuqin Zang (Tianjin Medical University, China) 14:15-14:45 Artificial intelligence in medicine
Yoon-Sup Choi (Digital Healthcare Institute, Korea) THURSDAY 15:15-15:25 The distribution and prevalence of high-risk human papillomavirus of women in western China: a meta-analysis 15:05-16:35 [Symposium 1] GBR B Rare Gynecologic Cancers: What is New? Mengpei Zhang (Sichuan University, China) Chair: Hextan Ngan (The University of Hong Kong, Hong Kong) 15:25-15:35 Differences in the results of evaluation of quality assurance Taek-Sang Lee (Seoul National University, Korea) between the two methods of provision of population-based cervical cancer screening in Japan 15:05-15:20 Ovarian clear cell carcinoma Eiko Aoki (International University of Health and Welfare, Mita Wen Yee Chay (National Cancer Centre Singapore, Singapore) Hospital, Japan) 15:20-15:35 Uterine leiomyosarcoma E Sun Paik (Samsung Medical Center, Korea) 15:35-15:45 A prospective randomized controlled study to compare thermal ablation with cryotherapy in cervical cancer 15:35-15:50 Trophoblastic disease update screening Yang Xiang (Peking Union Medical College Hospital, China) Dipanwita Banerjee (Chittaranjan National Cancer Institute, India) 15:50-16:05 Germ cell tumor Hiroyuki Fujiwara (Jichi Medical University, Japan) 15:45-15:55 Application of TERC and P16 FISH in triage of ASCUS Ying Li (Zhejiang University, China) 16:05-16:20 Low grade serous carcinoma Miseon Kim (CHA University, Korea) 15:55-16:05 Risk factors for type-specific HPV persistence after conization Yung-Taek Ouh (Korea University, Korea) 16:20-16:35 Discussion 16:05-16:15 Abnormal endocervical curettage (ECC) result is an 15:05-16:35 [Education Session 1] Room 204, 205 independent risk factor of positive margins in conization Radiation Gynecologic Oncology specimen Chair: Joo-Young Kim (National Cancer Center, Korea) Jian An (Fujian Medical University, China) Won Park (Samsung Medical Center, Korea) 16:15-16:25 GX-188E, a therapeutic HPV vaccine, in combination with 15:05-15:25 Locally advanced cervical cancer with lymph node positive on imiquimod or IL-7-HYFC for treatment of HPV-16 or HPV-18 image: chemoradiation first? related cin 3: results from phase 2 study Hyun-Cheol Kang (Seoul National University, Korea) Sungjong Lee (The Catholic University, Korea)
15:25-15:45 What is the best sequence of chemotherapy and radiotherapy 16:25-16:35 Quality assessment of websites providing information on HPV in locoregionally advanced endometrial cancer? vaccines in Thailand Jihye Cha (Yonsei University, Korea) Naratassapol Likitdee (Khon Kaen University, Thailand)
20 21 16:55-18:25 [Symposium 2] Cervical Cancer Screening in Asia GBR B 16:55-18:15 [Oral 2] Endometrial Hyperplasia/Cancer Room 206, 207 Chair: Jae-Kwan Lee (Korea University, Korea) Chair: Jaeman Bae (The Catholic University of Korea, Korea) Eiko Aoki (International University of Health and Sungjong Lee (The Catholic University of Korea, Korea) Welfare, Mita Hospital, Japan) 16:55-17:05 Comparison of diagnostic accuracy between endometrial 16:55-17:10 The distribution and prevalence of human papillomavirus in curettage and aspiration biopsy in patients treated with women in mainland China progestin for endometrial hyperplasia: a Korean gynecologic Rutie Yin (West China Second University Hospital of Sichuan oncology group study University, China) Mi Kyoung Kim (CHA University, Korea)
17:10-17:25 Korean national cervical cancer screening program 17:05-17:15 Diagnostic accuracy of MPap™ in women with abnormal Mina Suh (National Cancer Center, Korea) uterine bleeding for endometrial cancer: preliminary report of THURSDAY a multicenter validating confirmatory study 17:25-17:40 Japanese population-based cervical cancer management Hung-Cheng Lai (Taipei Medical University, Taiwan) system
Kumiko Saika (National Cancer Center, Japan) 17:15-17:25 The effect of combined progesterone and GnRH agonist on THURSDAY the growth of endometrial cancer cells 17:40-17:55 Cervical cancer screening in India Kyungjoo Cho (Gachon University, Korea) Seema Singhal (All India Institute of Medical Sciences, India) 17:25-17:35 Effect of megestrol acetate plus metformin as fertility-sparing 17:55-18:10 Cervical cancer screening in Myanmar treatment for patients with atypical endometrial hyperplasia Myint Myint Thinn (Central Women’s Hospital, Myanmar) and well-differentiated endometrial cancer. A randomized controlled trial 18:10-18:25 Discussion Bingyi Yang (Obstetrics and Gynecology Hospital of Fudan University, China) 16:55-18:25 [Education Session 2] Room 204, 205 Gyne-Oncologic Pathology 17:35-17:45 The oncologic outcome after fertility-sparing hormonal Chair: Hidetaka Katabuchi (Kumamoto University, Japan) management more than 9 months treatment for early stage Yong-Beom Kim (Seoul National University, Korea) endometrioid endometrial cancer Su Hyun Chae (Konkuk University, Korea) 16:55-17:15 Squamous cell carcinoma of the vulva and its precursors: does p53/p16 status matter? 17:45-17:55 Prolactin enhances the proliferation of endometrial glandular Kyu-Rae Kim (University of Ulsan, Korea) cells and endometrial cancer cells in conjunction with estradiol via regulation of prolactin receptor and estrogen 17:15-17:35 Mucinous ovarian tumor and pseudomyxoma receptor Chong Woo Yoo (National Cancer Center, Korea) Munekage Yamaguchi (Kumamoto University, Japan)
17:35-17:55 Molecular pathology and immunohistochemistry of 17:55-18:05 Selecting endometrial cancer patients for high risk of recurrence gynecologic malignancy Kailash Narayan (University of Melbourne, Australia) Daichi Maeda (Osaka University, Japan) 18:05-18:15 Using deep learning with convolutional neural network 17:55-18:15 Pathology of ovarian cancer precursors approach to identify the invasion depth of myometrium under Ren-Chin Wu (Chang Gung Memorial Hospital, Taiwan) MR images in early stage of endometrial cancer ~ a pilot study of TSGH in Taiwan 18:15-18:25 Discussion Cheng-Chang Chang (National Defense Medical Center, Taiwan)
22 23 NOTE THURSDAY
SCIENTIFIC PROGRAM
Friday, October 11 26
24 Friday, October 11 08:45-09:00 Pain management and anesthetic issue Jin-Tae Kim (Seoul National University, Korea) 08:30-10:00 [Symposium 3] GBR A Revised FIGO Stage of Cervix Cancer & Related Issues 09:00-09:05 Discussion Chair: Neerja Bhatla (All India Institute of Medical Sciences, India) 09:10-10:00 [Special Session 1] Room 206, 207 Jatupol Srisomboon (Chiang Mai University, Thailand) Molecular Dissection of Ovarian Clear Cell Carcinoma
08:30-08:45 Validating new (2018) FIGO staging of cervix cancer Chair: Aikou Okamoto (The Jikei University, Japan) Kailash Narayan (University of Melbourne, Australia) Jeong-Won Lee (Samsung Medical Center, Korea) 09:10-09:25 Ovarian clear cell carcinoma: molecular characterization of sensitivity to platinum-based chemotherapy 08:45-09:00 Pathologic perspectives in revised FIGO Masataka Takenaka (The Jikei University, Japan) Hyojin Kim (Seoul National University, Korea) 09:25-09:40 Molecular profiling of ovarian clear cell carcinomas: 09:00-09:15 Status of less-radical surgery in Japan implications for therapy Takahide Arimoto (Toranomon Hospital, Japan) Ruby Huang (National Taiwan University, Taiwan)
09:15-09:30 Predictive models for metastasis and recurrence after radical 09:40-09:55 Genomics to immunotherapy of ovarian clear cell carcinoma hysterectomy in patients with early-stage cervical cancer Katsutoshi Oda (The University of Tokyo, Japan) Kittipat Charoenkwan (Chiang Mai University, Thailand) 09:55-10:00 Discussion 09:30-09:45 Surgical staging in advanced stage Chel Hun Choi (Samsung Medical Center, Korea) 10:20-12:10 [Plenary Session 2] GBR A, B Surgical Issues in Gynecologic Oncology Field 09:45-10:00 Discussion Chair: Daisuke Aoki (Keio University, Japan) FRIDAY Young-Tae Kim (Yonsei University, Korea) 08:30-10:00 [Symposium 4] Endometrial Cancer Update GBR B nd 2 debulking in epithelial ovarian cancer FRIDAY Chair: Duk-Soo Bae (Samsung Medical Center, Korea) Qi Zhou (Chongqing University, China) 10:20-10:35 Surgery for recurrent ovarian cancer. Evidence from DESKTOP series and others Andreas du Bois (Kliniken Essen-Mitte, Germany) 08:30-08:50 How to avoid futile LND in early stage endometrial cancer Sokbom Kang (National Cancer Center, Korea) 10:35-10:50 GOG 213 surgical part Robert Coleman (University of Texas MD Anderson Cancer 08:50-09:10 LND issues in endometrial cancer Center, USA) Hidemichi Watari (Hokkaido University, Japan) 10:50-11:05 Selection criteria and principles for 2nd debulking surgery: 09:10-09:30 Molecular classification of endometrial cancer expert point of view Kidong Kim (Seoul National University, Korea) Dennis Chi (Memorial Sloan Kettering Cancer Center, USA)
09:30-09:50 Preservation of ovary in the management of endometrial 11:05-11:15 Discussion carcinoma Kun Song (Shandong University, China) Surgical approach in early stage cervical cancer after LACC 11:15-11:30 Real problems of laparoscopic radical hysterectomy 09:50-10:00 Discussion Joo-Hyun Nam (University of Ulsan, Korea)
08:30-09:05 [Education Session 3] ERAS Room 206, 207 11:30-11:45 Asian viewpoint Mikio Mikami (Tokai University, Japan) Chair: Dae-Sik Seo (University of Ulsan, Korea) 11:45-12:00 American and the other world viewpoint 08:30-08:45 Pre and postoperative management in gynecologic cancer Mario Leitao (Memorial Sloan Kettering Cancer Center, USA) surgery with planned bowel resection Jung Myun Kwak (Korea University, Korea) 12:00-12:10 Discussion
26 27 [한국로슈] 아바스틴 광고(영문)(2019)_105x210_190920_최종(인쇄용).pdf 1 2019. 9. 20. 오전 11:53
12:20-12:40 [Special Symposium 2] Sponsored by Roche GBR A, B Chair: Seob Jeon (Soonchunhyang University, Korea)
12:20-12:40 Role of bevacizumab in ovarian cancer & evolution as backbone of novel combination Mansoor R Mirza (Rigshospitalet Copenhagen University, Denmark) FRIDAY
28 15:15-15:30 Robotic approach for high-risk endometrial cancer 13:10-14:40 [Plenary Session 3] GBR A, B Jiheum Paek (Ajou University, Korea) PAPRi, Immuno-Oncology and Beyond Chair: Seung Cheol Kim (Ewha Womans University, Korea) 15:30-15:45 Sentinel lymph node staging experience in Thailand Xing Xie (Zhejiang University, China) Nuttavut Kantathavorn (HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Thailland) 13:10-13:30 PARP inhibition in ovarian cancer: is it time for a paradigm shift? 15:45-16:00 Two-step sentinel lymph node mapping strategy in Richard Penson (Massachusetts General Hospital, USA) endometrial cancer Sang-Wun Kim (Yonsei Cancer Center, Korea) 13:30-13:50 Prevalence of BRCA mutation and real world experience of PAPRi 16:00-16:15 Current role of minimally invasive surgery for ovarian cancer Byoung-Gie Kim (Samsung Medical Center, Korea) Jeong-Yeol Park (University of Ulsan, Korea)
13:50-14:10 Biomarkers for immunotherapy usage in gynecologic cancer 16:15-16:30 Discussion Wei Zhou (Merck Research Labotories, USA) 15:00-17:00 Ovarian Cancer Roundtable Session of Room 205 14:10-14:30 Novel and emerging agents under development for Chinese Gynecologic Oncologists gynecologic cancers 15:00-15:10 Opening Wen Yee Chay (National Cancer Centre Singapore, Singapore) Xing Xie (Zhejiang University, China) Rongyu Zang (Fudan University Zhongshan Hospital, China) 14:30-14:40 Discussion Part 1 15:00-16:30 [Symposium 5] GBR A Jihong Liu (Sun Yat-Sen University Cancer Center, China) FRIDAY Hereditary Breast and Ovarian Cancer in Asia Chair: Takayuki Enomoto (Niigata University, Japan) 15:10-15:40 Cornerstone·recent advances in surgery of ovarian cancer Wen-Fang Cheng (National Taiwan University, Taiwan) Jianqing Zhu (Zhejiang Cancer Hospital, China) FRIDAY
15:00-15:20 Establishing BRCA consortium in Asia 15:40-16:00 Discussion Sung-Won Kim (Daerim St. Mary’s Hospital, Korea) Discussion Leader: Yang Xiang (Peking Union Medical College Hospital, China) 15:20-15:40 Strategies of genetic test and counseling in Asia Masayuki Sekine (Niigata University, Japan) Part 2 Qi Zhou (Chongqing University, China) 15:40-16:00 Clinical impact of hereditary predisposition in gynecologic cancer 16:00-16:30 Milestone·advances in targeted therapy in ovarian cancer Myong-Cheol Lim (National Cancer Center, Korea) Rutie Yin (West China Second University Hospital of Sichuan University, China) 16:00-16:20 A need of Asian guidelines for the management of BRCA carrier 16:30-16:50 Discussion Arb-aroon Lertkhachonsuk (Mahidol University, Thailand) Discussion Leader: Yang Xiang (Peking Union Medical College Hospital, China) 16:20-16:30 Discussion 16:50-17:00 Closing 15:00-16:30 [Symposium 6] GBR B Xing Xie (Zhejiang University, China) MIS in Gynecologic Cancer Management Rongyu Zang (Fudan University Zhongshan Hospital, China) Chair: Nobuo Yaegashi (Tohoku University, Japan) Soo Young Hur (The Catholic University of Korea, Korea)
15:00-15:15 Sentinel lymph node biopsy in cervical and vulvar cancer Mario Leitao (Memorial Sloan Kettering Cancer Center, USA)
30 31 17:00-17:15 Comments on of the cervical cancer management 15:00-16:30 [Oral 3] TR in Ovarian Cancer Room 206, 207 Hung-Cheng Lai (Taipei Medical University, Taiwan) Chair: Sarikapan Wilailak (Ramathibodi Hospital, Thailand) Ting-Chang Chang (Chang Gung Memorial Hospital at 17:15-17:20 Discussion Linkou, Taiwan) 17:20-17:30 Case presentation: endometrial cancer 15:00-15:10 Antitumor effect of FGFR inhibitor AZD4547 in ovarian cancer cells Yiqin Wang (Peking University People's Hospital, China) Tae-Kyu Jang (Keimyung University, Korea) 17:30-17:45 Comments on various aspects of the case management 15:10-15:20 Survival prognosis of uterine-preserving surgery on stage I Janice Kwon (University of British Columbia, Canada) primary mucinous epithelial ovarian carcinoma Kaname Uno (Nagoya University, Japan) 17:45-17:50 Discussion
15:20-15:30 YAP silencing using dobutamine-PLGA nanoparticle as a new 17:50-18:00 Case presentation: epithelial ovarian cancer therapeutic strategy for ovarian cancer Won-Kyo Shin (National Cancer Center, Korea) Ju-Won Roh (Dongguk University, Korea) 18:00-18:15 Comments on various aspects of the case management 15:30-15:40 Tyrosine kinase receptor TIE-1 mediates cell growth by Masaki Mandai (Kyoto University, Japan) regulating PI3K/Akt signaling pathway in PI3K-high- expressing ovarian cancer. 18:15-18:20 Discussion Xuewei Zhang (Tohoku University, Japan)
16:50-18:10 [Oral 4] Issues in Surgical Treatment Room 206, 207 15:40-15:50 First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) Chair: Kung-Liahng Wang (Taitung Mackay Memorial Hospital, Taiwan) FRIDAY with advanced solid tumors. Wen Yee Chay (National Cancer Centre Singapore, Singapore) Yoon-Soon Lee (Kyungpook National University, Korea) FRIDAY 15:50-16:00 The roles of androgen receptor in chemosensitivity in serous 16:50-17:00 Risk factors for lymph node metastasis according to LVSI in ovarian cancer apparent uterine-confined endometrial cancer Hung-Chun Fu (Chang Gung Memorial Hospital, Taiwan) Joo-Hyuk Son (Ajou University, Korea)
16:00-16:10 Cancer stem cell (CD133, CD44 and ALDH1A1) markers as 17:00-17:10 Development of novel diagnosis method of uterine cancer prognostic factors on epithelial ovarian cancer using lymph node metastasis predictive biomarker for more Nugraha Pelupessy (University of Hasanuddin, Indonesia) personalized lymphadenectomy Emiko Yoshida (Juntendo University, Japan) 16:10-16:20 Low expression of gamma-glutamyl transpeptidase 1 is an independent poor prognostic factor associated with up- 17:10-17:20 Comparison of ROMA algorithm and CA 125 as tools for regulation of immune suppressive genes and EMT-related discriminate benign ovarian tumor and early stage ovarian genes in ovarian clear cell carcinoma cancer according to imaging tumor subtypes that connected Hiroshi Asano (Hokkaido University, Japan) to postoperative histopathologic findings Youngjae Lee (University of Ulsan, Korea) 16:20-16:30 The role Of Akt2, and CA-125 serum levels as predictors for cytoreduction in epithelial ovarian cancer surgery 17:20-17:30 Inadvertent ovarian malignancy following operative Yudi Mulyana Hidayat (Padjadjaran University, Indonesia) laparoscopy of adnexal masses: university malaya medical centre experience 16:50-18:20 [Education Session 4] GBR A Muhammad Asyaraf Azizan (University Malaya Medical Surgical and Molecular Tumor Board Center, Malaysia) Chair: Sang Young Ryu (National Cancer Center, Korea) Xiaoping Li (Peking University people's hospital, China) 17:30-17:40 Analysis of factors influencing the recurrence and fertility outcomes of ovarian borderline tumors 16:50-17:00 Case presentation: cervix cancer Zhengmao Zhang (Hebei Medical University, China) U Chul Ju (Chonnam National University, Korea)
32 33 17:40-17:50 The effect of pelvic and para-aortic lymphadenectomy for clinically-apparent stage I endometrioid epithelial ovarian carcinoma Masato Yoshihara (Nagoya University, Japan)
17:50-18:00 Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary Shohei Iyoshi (Nagoya University, Japan)
18:00-18:10 Knowledge, attitude and practices of gynecologists in a tertiary hospital on preoperative bowel preparation Romelyn Imperio-Onglao (Philippine General Hospital, Philippines)
16:50-18:20 [Special Session 2] ASGO-AOGIN Joint Session: GBR B How to Collaborate to Eliminate Cervical Cancer in Asia- Pacific Region Chair: EH Tay (AOGIN President, Singapore) Young-Tak Kim (University of Ulsan, Korea)
16:50-17:10 Elimination of cervical cancer: global overview and prospects for Asia Neerja Bhatla (All India Institute of Medical Sciences, India) SCIENTIFIC PROGRAM FRIDAY 17:10-17:30 VIA with picture as one option strategy in increasing the cervical cancer screening coverage in low resource setting area Dwiana Ocviyanti (Universitas Indonesia AOGIN, Indonesia) Saturday, October 12 36
17:30-17:50 HPV test as a primary cervical cancer screening Warner Huh (University of Alabama at Birmingham, USA)
17:50-18:10 Cost-effectiveness of primary HPV test and triage test in cervical cancer screening Wichai Termrungruanglert (Chulalongkorn University, Thailand)
18:10-18:20 Discussion
34 Saturday, October 12 09:10-09:20 Genomic comparison of endometrioid endometrial carcinoma and its precancerous lesions 08:30-10:00 [Special Session 3] GBR A Xuan Zong (Peking Union Medical College, China) International Research Collaboration through GCIG Chair: Kazunori Ochiai (Shin-Yurigaoka General Hospital, Japan) 09:20-09:30 Clinicopathologic significance of mismatch repair protein Jae-Weon Kim (Seoul National University, Korea) expression in endometrial cancer Mi-Kyung Kim (Ewha Womans University, Korea) 08:30-08:45 Role of GCIG on changing the practice in gynecologic cancer patients 09:30-09:40 Long term outcome of young patients with mismatch-repair Keiichi Fujiwara (Saitama Medical University International deficient endometrial carcinoma Mandy Man Yee Chu (The University of Hong Kong, Hong Kong) Medical Center, Japan)
09:40-09:50 Mutation landscape of germline and somatic BRCA1/2 genes 08:45-09:00 Operation and harmonization for international clinical trial in high-grade serous ovarian cancer patients management Kyung Jin Eoh (Yonsei University, Korea) Yusuke Kajimoto (Gynecologic Oncology Trial and Investigation Consortium of North Kanto, Japan) 09:50-10:00 Hormone replacement therapy after premature surgical menopause and health services utilization 09:00-09:15 Cervix & CCRN Ji-Hyun Jang (The University of British Columbia, Canada) Sang-Young Ryu (National Cancer Center, Korea)
08:30-08:50 [Poster Discussion] Room 204, 205 09:15-09:30 Ovarian cancer Rongyu Zang (Fudan University Zhongshan Hospital, China) 08:30-08:50 Selected poster discussion: merits and demerits Yoo-Young Lee (Samsung Medical Center, Korea) 09:30-09:45 Endometrial cancer
Jae-Weon Kim (Seoul National University, Korea) 09:00-10:00 [Education Session 5] Room 204, 205 Uterine and Cervical Cancer Surgery 09:45-10:00 Discussion Chair: Ju Won Roh (Dongguk University, Korea) Joong Sub Choi (Hanyang University, Korea) 08:30-10:00 [Oral 5] TR & Hereditary Room 206, 207
Chair: Efren Domingo (University of The Philippines, Philippines) 09:00-09:15 Radical hysterectomy Dae-Hoon Jeong (Inje University, Korea) Dae-Yeon Kim (University of Ulsan, Korea)
08:30-08:40 Development and preclinical testing of patient-derived 09:15-09:30 LEER
SATURDAY xenograft(PDX) models for uterine cancer Hee-Seung Kim (Seoul National University, Korea) Soo Young Jeong (Samsung Medical Center, Korea) 09:30-09:45 TMMR for cervical cancer 08:40-08:50 LncRNA RP11-395G23.3, as a competitive endogenous RNA, Rainer Kimmig (University Hospital Essen, Germany) regulate PTEN expression by sponging miR-205-5p in the SATURDAY progression of endometrial cancer 09:45-10:00 PMMR for endometrial cancer Weijuan Xin (Obstetrics and Gynecology Hospital of Fudan Rainer Kimmig (University Hospital Essen, Germany) University, China) 10:20-11:05 [Special Session 4] GBR A 08:50-09:00 Calcium channel CAV1.3 participates in epithelial- Clinical Trial in Asia: Can We Make a Quantum Jump? mesenchymal transition of endometrial cancer cells induced Chair: Wen Yee Chay (National Cancer Centre Singapore, by transforming growth factor β Singapore) Yibo Dai (Peking University, China) Jae-Hoon Kim (Yonsei University, Korea)
09:00-09:10 Pharmacogenomic analysis of patient-derived tumor cells in 10:20-10:35 Overview of the current status of clinical trials in Asia gynecologic cancers Kosei Hasegawa (Saitama Medical University, Japan) Jeong-Won Lee (Samsung Medical Center, Korea) 10:35-11:05 Discussion
36 37 10:38-10:47 Single-port laparoscopic radical trachelectomy with 10:20-11:30 [Oral 6] Cervical Cancer & GTN Treatment Room 206, 207 fluorescent image-guided sentinel lymph node dissection Chair: Sang Hoon Kwon (Keimyung University, Korea) Sang Wun Kim (Yonsei University, Korea) Dong Choon Park (The Catholic University of Korea, Korea) 10:47-10:56 Robotic single-port surgical staging for endometrial cancer 10:20-10:30 Ovarian metastasis in early-stage cervical cancer: a large using da Vinci SP® surgical system single institution study Jung Hun Lee (Kuyngpook National University, Korea) Kittipat Charoenkwan (Chiang Mai University, Thailand) 10:56-11:05 Laparoscopic primary repair of duodenal perforation after 10:30-10:40 Impact of learning curve on the survival of abdominal or laparoscopic para-aortic lymphadenectomy minimally invasive radical hysterectomy for early stage Hyeon Myeong Hong (Hanyang University, Korea) cervical cancer Hwajung Lee (Yonsei University, Korea) 11:05-11:50 [Film 1B] Room 204, 205 Chair: Andri Andrijono (University of Indonesia, Indonesia) 10:40-10:50 Impact of obesity on clinical outcomes in patients with early- Noh-Hyun Park (Seoul National University, Korea) stage cervical cancer after radical hysterectomy with pelvic
node dissection 11:05-11:14 Cervical cancer surgery Kittinun Leetanaporn (Prince of Songkhla University, Thailand) Zhengmao Zhang (RGCIRC, DELHI, China)
10:50-11:00 Post-irradiation PD-L1 expression predicts better 11:14-11:23 Laparoscopic extraperitoneal systematic pelvic and PARA- prognosis after carbon ion radiotherapy in uterine cervical aortic lymphadenectomy adenocarcinoma Supachai Raungkaewmanee (National Cancer Institute, Moito Iijima (Keio University, Japan) Thailand)
11:00-11:10 Comparisons of radiotherapy outcomes in cervical squamous 11:23-11:32 Nerve sparing modified laparoscopic radical hysterectomy cell carcinoma stage IIIB with and without lymph node with vaginal cuff closure and without uterine manipulator enlargement Dae-yeon Kim (University of Ulsan, Korea) Fitriyadi Kusuma (University of Indonesia, Indonesia) 11:32-11:41 Single-site robotic staging surgery for early stage ovarian cancer 11:10-11:20 Clinical significance of centralized surveillance of Ji Geun Yoo (The Catholic University, Korea) hydatidiform mole: five years' experience from a regional hospital in China 11:41-11:50 Combined technique of single-site robot and laparoscopy in Lan-zhou Jiao (Dalian Medical University, China) comprehensive staging operation of endometrial cancer Bo-Ra Lee (Chung-Ang University, Korea) SATURDAY 11:20-11:30 Gestational trophoblastic neoplasia: determinants of outcome 11:10-12:00 [Education Session 6] GBR A Seema Singhal (All India Institute of Medical Sciences, India) Training Session for Young Investigator and Research Nurse SATURDAY Chair: Rongyu Zang (Fudan University Zhongshan Hospital, 10:20-11:05 [Film 1A] Room 204, 205 China) Chair: Xiaohua Wu (Fudan University Shanghai Cancer Center, Byoung-Gie Kim (Samsung Medical Center, Korea) China) Keun Ho Lee (The Catholic University of Korea, Korea) 11:10-11:25 The Role of the CRC in an investigator initiated trial Ju Yeon Yi (RCONNECT, Korea) 10:20-10:29 Laparoscopic radical hysterectomy without uterine manipulator for early stage cervical cancer 11:25-11:40 The role and environment of research nurse Huaiwu Lu (Sun Yat-sen Memorial Hospital, China) Noriko Fujiwara (The University of Tokyo, Japan)
10:29-10:38 Clinical anatomy required in identifying pelvic autonomic 11:40-11:55 How to start investigator-initiated study? nerve system Jung-Yun Lee (Yonsei University, Korea) Yasuhiko Shiki (Osaka Rosai Hospital, Japan) 11:55-12:00 Discussion
38 39 Zejula is the rst PARP inhibitor approved for maintenance treatment of recurrent high-grade 12:10-12:30 [Special Symposium 3] Sponsored by Takeda GBR A Chair: Sunghoon Kim (Yonsei University, Korea) serous epithelial ovarian cancer after a response to platinum-based 12:10-12:30 New PARP inhibitor in recurrent ovarian cancer, regardless of chemotherapy regardless of BRCA status. BRCA status: the role of niraparib Aikou Okamoto (The Jikei University, Japan) SATURDAY
40 13:00-14:00 [Symposium 7] Fertility Preservation Upfront GBR A 14:05-15:05 [Symposium 8] GBR A Chair: Jihong Liu (Sun Yat-Sen University Cancer Center, China) Chemotherapy and Related Supportive Care Kimio Ushijima (Kurume University, Japan) Chair: Suresh Kumarasamy (Penang Medical College, Malaysia) Taejin Kim (Konkuk University, Korea) 13:00-13:15 Radical trachelectomy for young patients with early cervical cancer: the past and the future 14:05-14:20 Post chemotherapy quality of life in developing country Jin Li (Fudan University, China) Hariyono Winarto (Universitas Indonesia, Indonesia)
13:15-13:30 Fertility preserving treatment of early stage endometrial cancer 14:20-14:35 Hypersensitivity reactions to carboplatin and paclitaxel: Xiaojun Chen (Hospital of Fudan University, China) management and oncologic outcomes Suwanit Therasakvichya (Mahidol University, Thailand) 13:30-13:45 Fertility preservation in early stage epithelial ovarian cancer Hiroaki Kajiyama (Nagoya University, Japan) 14:35-14:50 Hospice care by specialist palliative care team Yoon Jung Chang (National Cancer Center, Korea) 13:45-14:00 Fertility preservation for female cancer patients Yutaka Osuga (The University of Tokyo, Japan) 14:50-15:05 Pain control in patients with advanced stage cancer Seyoung Seo (University of Ulsan, Korea) 13:00-14:00 [Education Session 7] Room 204, 205 Imaging in Ovarian Cancer Practice 14:05-15:05 [Oral 7] Room 206, 207 Chair: Jae Hong No (Seoul National University Bundang Medical Treatment in Ovarian Cancer Hospital, Korea) Chair: Yong Jung Song (Pusan National University, Korea) Seung-Su Han (Chung-Ang University, Korea) Kwang-Beom Lee (Gachon University, Korea)
13:00-13:15 Imaging study before cytoreductive surgery 14:05-14:15 Bevacizumab maintenance therapy extended the overall Byung Kwan Park (Samsung Medical Center, Korea) survival for the histopathological mesenchymal transition type of high-grade serous ovarian carcinoma 13:15-13:30 Imaging follow up strategy of ovarian cancer Kentaro Ishida (Nagahama Red Cross Hospital, Japan) Jeong Yeon Cho (Seoul National University, Korea) 14:15-14:25 Additional chemotherapy in epithelial ovarian cancer with 13:30-13:45 Functional Imaging of ovarian cancer residual disease after six cycles of postoperative adjuvant Dae Chul Jung (Yonsei University, Korea) chemotherapy Se Ik Kim (Seoul National University, Korea) 13:45-14:00 Response evaluation: RECIST & iRECIST on imaging SATURDAY Sung Yoon Park (Samsung Medical Center, Korea) 14:25-14:35 Preliminary experience of hyperthermic intraperitoneal chemotherapy after debulking surgery for ovarian cancer 13:00-14:00 [Special Session 5] Room 206, 207 Wei-Chun Chen (Chang Gung Memorial Hospital, Taiwan)
From Good Research to Good Publication SATURDAY Chair: Ki Hyung Kim (Pusan National University, Korea) 14:35-14:45 Enhanced chemotherapy effects on gynecological cancers by Chunling Chen (Peking University, China) using the combination of lipid bubble and ultrasound Kohei Yamaguchi (The University of Tokyo, Japan) 13:00-13:20 Ethical review of the research project Yawana Tanapat (Bumrungrad International Hospital, 14:45-14:55 Doxorubicin-loaded oligonucleotide conjugated gold Thailand) nanoparticles: a promising drug delivery system for ovarian cancer 13:20-13:40 Tips for success as a clinical investigator Hee Kyeong Seo (Soonchunhyang University, Korea) Soyi Lim (Gachon University, Korea) 14:55-15:05 The influence of depression on health utility value in patients 13:40-14:00 Transparency in medical writing with gynecologic cancer: a comparison with physical Seung-Hyuk Shim (Konkuk University, Korea) symptoms and performance status Hyemin Yeo (National Cancer Center, Korea)
42 43 14:05-15:05 [Education Session 8] Room 204, 205 Ovarian Cancer Surgery Chair: Chi-Heum Cho (Keimyung University, Korea) Chih-Ming Ho (Cathay General Hospital, Taiwan)
14:05-14:20 Surgical technique: radical upper abdominal dissection/ resection Suk-Joon Chang (Ajou University, Korea)
14:20-14:35 Surgical technique: radical pelvic dissection/resection Kazuyoshi Kato (Tokyo Medical University, Japan)
14:35-14:50 MSKCC resectability score and selection criteria for primary debulking surgery Dennis Chi (Memorial Sloan Kettering Cancer Center, USA)
14:50-15:05 Role of lymphadenectomy in ovarian cancer Jianqing Zhu (Zhejiang Cancer Hospital, China)
15:05-15:20 [Closing Ceremony] GBR A POSTER
Poster Discussion 46 Poster Display 48 SATURDAY
44 Poster Discussion Room 204, 205 PD11 Genetic profiling and clonal evolution in ovarian yolk sac tumor Xuan Zong (Peking Union Medical College Hospital, Chinese Saturday, October 12, 08:30-08:50 Academy of Medical Sciences and Peking Union Medical College, China) Cancer Screening PD01 Primary screening for cervical cancer based on high-risk human Rare Tumors including Uterine Sarcoma & GTD papillomavirus (HPV) detection in Zhejiang province, Southeast China Qiongyan Wu (Zhejiang University, China) PD12 Clinical sequencing by todai oncopanel (TOP) for uterine sarcomas Hirofumi Inaba (The University of Tokyo, Japan) PD02 Evaluation of cell-free DNA from papanicolaou smear and peripheral blood to detect endometrial cancer Fertility Preservation Xuan Zong (Peking Union Medical College, China) PD13 Modified laparoscopic radical trachelectomy for early stage cervical cancer Invasive Cervical Cancer Xiaoting Ling (Sun Yat-Sen University, China) PD03 Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma - updated survival Translational Research outcomes and experience in post radiation surgery Jiaxin Yang (Peking Union Medical College, China) PD14 The role of hyperactive homologous recombination in survival outcomes of platinum treated ovarian carcinoma Michal M Hoppe (Cancer Science Institute of Singapore, National Epithelial Ovarian Cancer University of Singapore, Singapore) PD04 Impact on overall survival of non-specific death in early-stage epithelial ovarian cancer patients: a SEER database analysis PD15 Induction of anti-VEGF therapy resistance by upregulated expression Danian Dai (Sun Yat-Sen University, China) of microseminoprotein (MSMP) Takashi Mitamura (Hokkaido University, Japan) PD05 Cost-effectiveness of tumor testing for BRCA mutations in high- grade serous ovarian cancer for PARP inhibitor maintenance therapy Janice Kwon (University of British Columbia, Canada)
PD06 Rosiglitazone ameliorates senescence-like phenotypes in ovarian cancer Jianwen Gao (Osaka University, Japan)
PD07 Gonadotropin-releasing hormone receptor-targeted near-infrared fluorescence probe for specific recognition and localization of peritoneal metastases of ovarian cancer Qiyu Liu (Obstetrics and Gynecology Hospital of Fudan University, China)
PD08 A clinicopathologic multivariate analysis in effects of Intraepithelial carcinoma on patients with mucinous borderline ovarian tumors Rui-fang Chen (Obstetrics and Gynecology Hospital of Fudan University, China)
Non-epithelial Ovarian cancer PD09 Does comprehensive surgical staging determine the oncological outcome of malignant ovarian germ cell tumour? Anu Joseph (All India Institute of Medical Sciences, India)
PD10 Salvage therapy for patients with recurrent and persistent malignant ovarian germ cell tumors Jinhui Wang (Peking Union Medical College, China)
46 47 Poster Display P011 The American society for colposcopy and cervical pathology (ASCCP) 2017 risk-based colposcopy practice recommendations when Cancer Screening applied for Thai women with ASC-US or LSIL cervical cytology P001 Challenges of management of gynecological cancer in LMIC Rattiya Phianpiset (Mahidol University, Thailand) Aliya Begum (Aga Khan University Hospital, Pakistan) Pre-invasive Disease of Uterine Cervix P002 Evaluation of high-risk human papillomavirus genotyping and non- P012 HPV infection and p16 promoter methylation as predictors of ASC- genotyping assays for cervical cancer screening, a real-world study in US/ LSIL progression China Dan-Ah chae (Chung-Ang University, Korea) Binhua Dong (Fujian University, China) P013 Comparision of histological outcomes from pre-menopausal P003 Distribution of human papillomavirus genotypes in 533 women with and post-menopausal women with report of cervical cytological cervical lesions in Chongqing, Southwest China abnormality Dongling Zou (Chongqing University Cancer Hospital, China) Eunhyun Lee (Inje University, Korea)
P004 Utility of human papillomavirus L1 capsid protein and HPV test as P014 Expectant management of pregnant and postpartum women with prognostic markers for cervical intraepithelial neoplasia 2+ in women cervical intraepithelial neoplasia with persistent ASCUS/ LSIL cervical cytology Hidenori Sasa (National Defense Medical College, Japan) Eun Young Ki (The Catholic university of Korea, Korea) P015 The risk of high-grade cervical intraepithelial neoplasia (CIN) and P005 Efficacy of trichloroacetic acid (TCA) compared to cryotherapy in cancer in patients aged 65 years or older with abnormal cervical treating patients with positive IVA result cancer screening test Herdhana Suwartono (INASGO, Indonesia) Hyun-Woong Cho (Korea University, Korea)
P006 Impact of visual inspection of the cervix after application with P016 Management of cervical intraepithelial neoplasia 2 in young women acetic acid (VIA) followed by cryotherapy treatment (see and treat Jooyoung Kim (Seoul National University, Korea) approach) for secondary cervical cancer prevention in Pathein Township, Myanmar P017 Usefulness of human papillomavirus genotyping to predict Htun Lynn Soe (Central Women's Hospital, Myanmar) residual/ recurrent disease after conservative treatment of cervical intraepithelial neoplasia compared with HPV DNA testing P007 Cervical cancer screening trends and geographical distribution in Kouichiro Kawano (Kurume University, Japan) Japan Kanako Kono (Keio University Graduate School of Medicine/ National P018 The impact of vaginal microbiota on the cervical carcinogenesis Cancer Center, Japan) Kyeong A So (Konkuk University, Korea)
P008 The effectiveness of human papillomavirus (HPV) self-sampling P019 New diagnostic device for cervical dysplasia using electrical testing on cervical cancer screening in a community impedance imaging Kim Seng Law (Tung`s Taichung Metro Harbor Hospital, Taiwan) Dong Choon Park (Kyung Hee University, Korea)
P009 Profiling of serum metabolites using MALDI-TOF and Triple-TOF mass P020 Cervical intraepithelial neoplasia-2 of women in their twenties: spectrometry to develop a screen for ovarian cancer which is the best management? Mi-Kyung Kim (Ewha Womans University, Korea) Miseon Kim (CHA University, Korea)
P010 A correlation of reporting cervical cytology between gravity P021 Diagnostic inaccuracy of colposcopy-directed biopsy in women with sedimentation liquid-based cytology and conventional cytologic high-grade squamous intraepithelial lesion: immediate papanicolaou smears loop electrosurgical excision procedure may be a better strategy Nattapong Sermsukcharoenchai (Phramongkutklao Hospital, Se Ik Kim (Seoul National University, Korea) Thailand)
48 49 P022 The role bacille calmette-guerin BCG TO low grade cervical P034 Comparison of laparoscopic and abdominal radical hysterectomy precancerous lesions in early stage cervical cancer patients without adjuvant treatment: Tendi Robby Setia (Hasan Sadikin Hospital, Indonesia) ancillary analysis of a Korean gynecologic oncology group study (KGOG 1028) P023 Cervical intraepithelial neoplasia and risk of gynecologic cancer: a E Sun Paik (Samsung Medical Center, Korea) nationwide cohort study Yung-Taek Ouh (Korea University, Korea) P035 BRCA1 immunohistochemistry expression and survival in cervical cancer Pre-invasive Disease and Cancer of Vulvo-Vagina E Sun Paik (Samsung Medical Center, Korea)
P024 Basal cell carcinoma of the vulva: a case report P036 Pembrolizumab for unresectable recurrent cervical cancer - pilot Aubrey Seneris (Philippine General Hospital, Philippines) experience in a tertiary center of Taiwan
Hsiu-Jung Tung (Chang Gung Memorial Hospital Linkou branch, Taiwan) P025 The risk factors of high-grade vaginal intraepithelial neoplasia (VaIN)
and cancer: single institution experience P037 Long-term results of minimally invasive versus abdominal radical Hyun-Woong Cho (Korea University, Korea) hysterectomy in patients with early cervical cancer
Hyun Park (CHA University, Korea) P026 A case report and literature review of primary vaginal NK/T
lymphoma P038 Selection criteria and colpotomic approach for safe minimally Luo Yan (Sichuan University, China) invasive radical hysterectomy in early-stage cervical cancer
Joo-Hyuk Son (Ajou University, Korea) P027 Experience of treatment of vulvar malignancies in a regional tertiary
centre in Southeast Asia P039 Risk factor for the postoperative lymphocele in women with Qi Maili (KK Women’s and Children’s Hospital, Singapore) cervical cancer treated with radical hysterectomy and pelvic
lymphadenectomy P028 Recurrent paget’s disease of the vulva in a split-thickness graft Jung Hwan Ahn (The Catholic University of Korea, Korea) RomelynImperio-Onglao (Philippine General Hospital, Philippines)
P040 Clinical significance of the pattern-based classification in P029 A rare case of invasive vaginal carcinoma post vaginal hysterectomy endocervical adenocarcinoma, usual and variants RomelynImperio-Onglao (Philippine General Hospital, Philippines) Jung Mi Byun (Inje University, Korea)
P030 Carcinoma of vulva, case series P041 Single port access laparoscopic radical hysterectomy for early-stage Saujanya Karmacha rya (IGCS, Civil Service Hospital, Nepal) cervix cancer running title: SPA LRH for cervical cancer
Kyung Jin Eoh (Yonsei University, Korea) P031 Vaginal stripping for vaginal intraepithelial neoplasia (VAIN)
Yu Ka Chai (Queen Mary Hospital, Hong Kong) P042 Clinical characteristics and prognosis of cervical cancer among Filipino women ages 35 years old and below: a retrospective cohort Invasive Cervical Cancer study P032 Phase i study of a B cell- and monocyte-based immunotherapeutic Limavel Ann Veloso (Society of Gynecologic Oncologists of the vaccine, BVAC-C in human papillomavirus type 16- or 18-positive Philippines, Philippines) recurrent cervical Cancer Chel Hun Choi (Samsung Medical Center, Korea) P043 Paclitaxel plus cisplatin as adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIB cervical P033 Post-surgical prognosis of low and medium-risked cervical cancer cancer and its correlation with adjuvant treatment Mashiro Shimomura (Osaka City University, Japan) Chihiro Ishizawa (The University of Tokyo, Japan) P044 Early experiences of treatment with pembrolizumab in recurrent gynecologic malignancies Min Chul Choi (CHA University, Korea)
50 51 P045 Profile of trachelectomy in women with early-stage cervical cancer: a P057 Corelation between tumor size and neoadjuvant chemotherapy nationwide cohort study in Japan response in cervical cancer stage IB2 and IIA2 Miwa Yasaka (Tokai University, Japan) Syamel Muhammad (Andalas University, Indonesia)
P046 Pulmonary lymphangitic metastasis in cervical cancer: case series P058 Prognosis of stage IIIC uterine cervical cancer following hysterectomy Myeong Seon Kim (Sungkyunkwan University, Korea) and radiotherapy: validation of revised FIGO staging Won Kyung Cho (Sungkyunkwan University, Korea) P047 Anti-tumor effects of tetraarsenic oxide (TAO, As4O6) in human cervical cancer P059 Significance of tumor size in IB-IIA cervical cancer with pathologic Myeong Seon Kim (Sungkyunkwan University, Korea) risk factors following hysterectomy Won Kyung Cho (Sungkyunkwan University, Korea) P048 Effectiveness of neoajuvant chemotherapy in cervical carcinoma (FIGO stage IB2, IIA2 and IIB) P060 Measures to prevent tumor spillage in laparoscopic surgery and Ni Ni Thein (Central Women's Hospital, Myanmar) outcome of total laparoscopic and abdominal radical hysterectomy for FIGO 1B1-2 cervical cancer P049 A case of primary signet ring cell carcinoma of the uterine cervix Yasuhiko Shiki (Osaka Rosai Hospital, Japan) treated with CPT-11/S-1 therapy Rikako Soma (Iwate Medical University, Japan) P061 Triplet chemotherapy versus doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer P050 The texture analysis of FDG PET/CT in cervical cancer Yoo-Young Lee (Samsung Medical Center, Korea) Ruri Otaki (Osaka Medical College Hospital, Japan) P062 Value of adjuvant chemotherapy using paclitaxel plus carboplatin P051 Comparative outcomes between abdominal and tumor-sealing after radical surgery with or without radiotherapy in stage IB-IIA laparoscopic radical hysterectomy in cervical cancer : results from a cervical adenocarcinoma with risk factors single surgeon's experience You Wu (National Center/Cancer Hospital, Chinese Academy of Sang Il Kim (The Catholic University of Korea, Korea) Medical Sciences and Peking Union Medical College, China)
P052 Impact of laparoscopic radical hysterectomy on survival outcome in P063 Prognosis of early-stage neuroendocrine carcinomas of the cervix: patients with FIGO stage IB cervical cancer: a matching study of two study at a Japanese single institute institutional hospitals in Korea Yusuke Kobayashi (Keio University, Japan) Se Ik Kim (Seoul National University, Korea) P064 Protective effect of magnesium supplementation on cisplatin- P053 Outcome of patients with uterine cervical cancer undergoing radical induced renal toxicity in patients with uterine cervical cancer hysterectomy using the 2018 FIGO staging Yuta Inoue (Osaka City University, Japan) Seiya Sato (Iwate Medical University, Japan) P065 Sentinel lymph nodes mapping can predict the state of peritoneal P054 Learning curve could affect the surgical outcome of radical lymph nodes metastasis in early-stage cervical cancer hysterectomy in cervical cancer Zhengmao Zhang (Hebei Medical University, China) Seongmin Kim (Korea University, Korea) Epithelial Ovarian Cancer P055 A clinicopathological analysis of 2,378 patients with FIGO 2018 stage P066 Olaparib maintenance therapy for the recurrent high-grade serous IB1/IB2 cervical cancer by Japanese gynecologic oncology group ovarian carcinoma: a single center experience network (JGOG 1072s) Akihiko Ueda (Kyoto University, Japan) Shogo Shigeta (Tohoku University, Japan)
P067 Serum lactate dehydrogenase is a possible predictor of platinum P056 Factors that influence 1 year survival rate in cervical cancer patient at resistance in ovarian cancer Wahidin Sudirohusodo hospital, Makassar, Indonesia Asami Ikeda (National Hospital Organization Kyoto Medical Center, Suci Amaliah Syarief (Hasanuddin University, Indonesia) Japan)
52 53 P068 The comparative analysis of clinicopathologic characteristics P079 Circulating tumor DNA in epithelial ovarian cancer between seromucinous borderline ovarian tumors (SMBOTs) and Hee Kyoung Song (The Catholic University of Korea, Korea) mucinous borderline ovarian tumors (MBOTs) Beibei Wu (Obstetrics and Gynecology Hospital of Fudan University, P080 Evaluation of efficacy and safety of bevacizumab for advance and China) recurrent mullerian carcinoma in our institution. Hiroaki Matsubara (Osaka City University, Japan) P069 The outlook of treatment of ovarian clear cell carcinoma (CCC) ? in molecular aspect P081 Trends and characteristics of epithelial ovarian cancer between Japan Chen-Bin Chang (Chang Gung Memorial Hospital, Taiwan) and the US: a JSGO?JSOG joint study Hiroko Machida (Tokai University, Japan) P070 Core immunological functions involved in ovarian clear cell carcinoma discovered by the gene ontology-based P082 Malignant brenner tumor of the ovary: a case report immunofunctionome analysis Humbeline Gaboy (Baguio General Hospital and Medical Center, Cheng-Chang Chang (Tri-Service General Hospital, National Philippines) Defense Medical Center, Taiwan) P083 Identification of cancer-related long non-coding RNAs before and P071 Differential promoter methylation and expression at RASSF1A after neoadjuvant chemotherapy in epithelial ovarian cancer between ovarian carcinoma stromal progenitor and cancer cells Jaein Kim (Yonsei University, Korea) predict survival outcome of epithelial ovarian cancer patients Chih-Ming Ho (Cathay General Hospital, Taiwan) P084 Clinical characteristics predictive of optimal primary cytoreduction in epithelial ovarian malignancy: a five-year retrospective study in a P072 Outcome of women unexpectedly diagnosed ovary cancer tertiary government Government Hospital Ching Yu Cheng (National Taiwan Universtiy, Taiwan) Jehada-Inn Misuari-Alihuddin (Philippine General Hospital, Philippines)
P073 Effectiveness of oral etoposide in recurrent or refractory epithelial P085 A prospective evaluation of tolerability of niraparib dosing based ovarian cancer and primary peritoneal cancer on baseline body weight and platelet count: blinded pooled interim Chompunoot Kongsawatvorakul (Ramathibodi Hospital, Thailand) safety data from the NORA Study Jia Zhang (Fudan University Shanghai Cancer Center, Indonesia) P074 Transmembrane G protein coupled receptor 30 (GPR30) gene polymorphisms in Korean women with ovarian cancer: an P086 The role and regulatory mechanism of CHD4 in epithelial ovarian experimental study cancer Dae Gy Hong (Kyungpook National University, Korea) Jieyu Wang (Obstetrics and Gynecology Hospital of Fudan University, China) P075 Real-world experience of olaparib maintenance in high grade serous recurrent ovarian cancer patients with BRCA 1/2 mutation: Korean P087 Prognostic analysis of splenic parenchymal metastasis in advanced multicenter study ovarian cancer: does the parenchymal metastasis matter? E Sun Paik (Samsung Medical Center, Korea) Joo-Hyuk Son (Ajou University, Korea)
P076 Clinicopahology characteristics of ovarian clear cell carcinoma P088 Safety and feasibility of preemptive cholecystectomy as part of patients at Cipto Mangunkusumo hospital on 2010 - 2015 cytoreductive surgery in advanced ovarian cancer Fitri Adinda Novianti Mahdi (Cipto Mangunkusumo Hospital, Joo-Hyuk Son (Ajou University, Korea) Indonesia) P089 Risk factors for postoperative morbidity for ovarian cancer patients P077 A case of ovarian serous borderline tumor in a 12-years-old girl undergoing primary debulking surgery Fumihiro Murakami (The Catholic University of Korea, Japan) Junchen Chen (Peking University People’s Hospital, China)
P078 The myelosuppresive effect and nephrotoxicity of chemotherapies in P090 Preoperative prognostic biomarkers in ovarian cancer ovarian cancer patients: a single-center study Junchen Chen (Peking University People’s Hospital, China) Hariyono Winarto (Universitas Indonesia, Indonesia)
54 55 P091 A preoperative risk score to predict intraoperative blood loss volume P103 Effect of BRCA mutational status on survival outcome in epithelial in patients undergoing hysterectomy for ovarian cancer primary peritoneal, ovarian, and fallopian tubal cancers: experience Junchen Chen (Peking University People’s Hospital, China) on germline BRCA1/2 gene testing at a tertiary institutional hospital in Korea P092 Feasibility of neoadjuvant chemotherapy containing bevacizumab Se Ik Kim (Seoul National University, Korea) and interval debulking surgery for advanced epithelial ovarian cancer: preliminary data P104 Colororectal and urologic surgery in advanced ovarian cancer, who Junsik Park (Yonsei University, Korea) should do it? Sigit Purbadi (University of Indonesia, Indonesia) P093 Chemotherapy response score is a prognostic factor in patients with ovarian cancer who underwent neoadjuvant chemotherapy and P105 Does inclusion of pegylated liposomal doxorubicin in the interval debulking surgery management of progressive or recurrent ovarian cancer improve Ken Matsukuma (Kurume University, Japan) overall survival? Sikarn Satitniramai (Mahidol university, Thailand) P094 A typical endometriosis associated with ovarian malignancy Kyeong A So (Konkuk University, Korea) P106 Integration of plasma proteomics and targeted plasma metabolomics data for serous ovarian cancer diagnosis P095 Inhibition of pten induces anti-proliferative effect on ovarian cancer Somi Oh (Gangnam Kwon's Gynecology Clinics, Korea) cells Kyungjoo Cho (Gachon University, Korea) P107 Impact of intervals between secondary cytoreductive surgery and adjuvant chemotherapy in patients recurrent epithelial ovarian P096 Modulation of tumor microenironment by chemotherapy in ovarian cancer cancer Soo Young Jeong (Sungkyunkwan University, Korea) Ling Lim (MacKay Memorial Hospital, Taiwan) P108 Mimicker of advanced ovarian cancer - peritoneal tuberculosis P097 Impact of pre-operative whey protein infused carbohydrate loading Sze Ki Hui (Hospital Authority, Hong Kong) and post-operative early oral feeding in ovarian cancer patients under fast tract surgery setting P109 A phase II study of irinotecan and pegylated liposomal doxorubicin Mohd Norazam Mohd Abas (National Cancer Institute, Malaysia) in platinum-resistant recurrent ovarian cancer(Tohoku gynecologic cancer unit 104 study) P098 Oncologic safety of closed suction technique in removal of huge Tadahiro Shoji (Iwate Medical University, Japan) ovarian cyst Nam-Kyeong Kim (Seoul National University, Korea) P110 Ovarian cancer stemness: biological and clinical implications for ovarian cancer metastasis and chemoresistance P099 Clinical characteristics of ovarian clear cell carcinoma in an Asian Takeshi Motohara (Kumamoto University, Japan) cohort Pearl Tong (NUHS, Singapore) P111 Clinicopathologic features and prognostic analysis of stage I ovarian clear cell cancer P100 Rash and ovarian cancer: a case of a paraneoplastic syndrome Tiantian Wang (Cancer Hospital, Chinese Academy of Medical Reya Hurtado (Philippine General Hospital, Philippines) Sciences and Peking Union Medical College, China)
P101 Recurrence patterns after treatment of bevacizumab in platinum- P112 Creatinin clearance vs glomerular filtration rate in platinum based sensitive recurrent epithelial ovarian cancer chemotherapy: which one is the best? Se Ik Kim (Seoul National University, Korea) Tofan Utami (FMUI, Indonesia)
P102 Impact of extended cycles of chemotherapy on survival outcome in P113 Intraoperative tumor lysis syndrome in a patient with advanced recurrent epithelial ovarian cancer ovarian cancer Se Ik Kim (Seoul National University, Korea) Wilasinee Areeruk (Srinakharinwirot University, Thailand)
56 57 P114 Utility of plasma circulating tumor DNA in ovarian cancer monitoring P125 Evaluation of myometrial invasion in type I endometrial cancer using Yoshiko Nanki (Keio University, Japan) magnetic resonance diffusion weighted imaging Hariyono Winarto (FKUI/RSCM, Indonesia) P115 Prevalence and predictors of hematological toxicity on adjuvant chemotherapy and the prognosis in geriatric patients with epithelial P126 Consideration of next regimen for advanced endometrial cancer with ovarian cancer: a two-center retrospective cohort study microsatellite instability Yuxi Zhao (Cancer Hospital Chinese Academy of Medical Science and Hyewon Chung (Keimyung University, Korea) Peking Union Medical College, China) P127 Comparison of surgical outcomes, 3-year disease free survival Non-epithelial Ovarian cancer rate and overall survival rate between single-port access staging laparoscopy and conventional staging laparoscopy in uterine cancer P116 Individualized significance of lymphadenectomy across all age Jee Whan Kim (Yonsei University, Korea) groups and histologies in malignant ovarian germ cell tumors
Jieyu Wang (Obstetrics and Gynecology Hospital of Fudan University, P128 Minimally invasive versus abdominal hysterectomy for endometrial China) carcinoma with glandular or stromal invasion of cervix
Yoo-Young Lee (Samsung Medical Center, Korea) P117 A case of ovarian mixed germ cell tumor with torsion
Saki Ishii (Sakai City Medical Center, Japan) P129 Survival outcomes of FIGO stage IIIC and IVB endometrial cancer
patients presenting primarily as nodal spreads without peritoneal P118 Inferior vena caval syndrom in paraaortic metastastic lession of carcinomatosis ovarian dysgerminoma in pregnancy manage with chemotherapy: a Joo-Hyuk Son (Ajou University, Korea) case report
Syamel Muhammad (Andalas University, Indonesia) P130 Risk factors for tumor recurrence in surgically managed endometrial
cancer: a cohort study P119 Ovarian mass in a patient with a strong history of cancer Kathleen Gizelle Alfonso (Society of Gynecologic Oncologists of the Zheng Yuan Ng (KK Women's and Children's Hospital, Singapore) Philippines, Philippines)
Endometrial Hyperplasia, EIN and Endometrial Cancer P131 Association of abnormal pap smear with occult cervical stromal P120 Feasibility of sentinel lymph node sampling in early stage carcinoma invasion in patients with endometrial cancer endometrium: experience from a developing country Kewalin Khumthong (Khon Kaen University, Thailand) Aswathy G Nath (RCC, Thiruvananthapuram, India) P132 When everything turns to black - Man: a sign of impending doom;;;; P121 Vaginal recurrence in sentinel lymph node biopsy-negative stage Malignant acanthosis nigricans (MAN) in a patient with endometrial ia endometrial carcinoma using near-infrared fluorescence with carcinoma indocyanine green dye Patricia Tanchuling (Philippine General Hospital, Philippines) Bernadette Yap (UP-Philippine General Hospital, Philippines) P133 Association of preoperative serum HE4 levels on survival of patients P122 Correlation of preoperative assessment by magnetic resonance with endometrial cancer imaging and clinicopathologic results in endometrial cancer Putsarat Insin (Rajavithi Hospital, Thailand) Chia-Ying Wu (National Taiwan University Hospital, Taiwan) P134 Successful removal of a peritoneovenous shunt for severe chylous P123 Comparison of laparoscopy and laparotomy for paraaortic ascites after a para-aortic lymphadenectomy: a case report lymphadenectomy in women with high-risk endometrial cancer Tsutomu Ida (Tokyo Metropolitan Tama Medical Center, Japan) E Sun Paik (Samsung Medical Center, Korea) P135 Have type 1 and 2 endometrial cancers the different P124 Tumor size as independent prognostic factor in stage IA clinicopathological features and survival outcomes? endometrioid endometrial adenocarcinoma U Chul Ju (Chonnam National University, Korea) Geminelle Co (Philippine General Hospital, Philippines)
58 59 P136 Clinicopathological and survival analysis of synchronous primary P147 A case of squamous cell carcinoma of unknown primary site endometrial and ovarian cancer: a single institution review of 29 Koichiro Lee (Sakai City Medical Center, Japan) cases U Chul Ju (Chonnam National University, Korea) P148 The accuracy of ultrasound in diagnosing first trimester molar pregnancy P137 Dual targeting of estrogen receptor α and estrogen-related receptor Renne Riza Medalla (Philippine General Hospital, Philippines) α: a novel endocrine therapy for endometrial cancer Xiaodan Mao (Fujian Medical University, China) P149 Giant uterine mass with uterine smooth muscle tumor of uncertain malignant potential: a case report P138 Doubting the prognostic significance of lymphovascular space Tae-Kyu Jang (Keimyung University, Korea) invasion to endometrioid endometrial cancer patients among Chinese population: a retrospective study of 584 cases from a single P150 Identifying the factors affecting chemotherapy resistance of single center agent methotrexate in gestational trophoblast neoplasia (gtn) low- Yibo Dai (Peking University People's Hospital, China) risk stage I, II and III therapy in Hasan Sadikin hospital West Java Tendi Robby Setia (Hasan Sadikin Hospital, Indonesia) P139 Comparison of outcome between one-step versus two-step sentinel lymph node biopsy in endometrial cancer P151 Twin pregnancy post external beam radiation therapy (EBRT) in Yoo-Na Kim (Yonsei University, Korea) gestational trophoblastic neoplasia (GTN) Invading to right cornu and vaginal metastasis treated with single-agent chemotherapy; all P140 Imaging-based definition of lower uterine segment carcinoma to treatments are safe to preserve fertility function improve the detection sensitivity of probable Lynch syndrome Tricia Dewi Anggraeni (University of Indonesia, Indonesia) Yukiharu Todo (Hokkaido Cancer Center, Japan) P152 PD-L1, B7-H3 and VISTA are highly expressed in gestational Rare Tumors including Uterine Sarcoma & GTD trophoblastic neoplasia Yang Xiang (Peking Union Medical College, China) P141 Embryonal rhabdomyosarcoma arising from uterine corpus in a
postmenopausal woman : a case report and literature review P153 Prediction of distant metastasis in patients with early ~ locally A-jaree Senthong (Surin Hospital, Thailand) advanced uterine sarcoma
Yeni Kim (University of Ulsan, Korea) P142 Undifferentiated endometrial sarcoma: an uncommon case report
Baasansuren Nyamkhuu (National Cancer Center, Mongolia) P154 Management and prognosis of relapsed gestational trophoblastic
neoplasia: a 14-year experience P143 Lymphocyte-monocyte ratio predicts uterine sarcoma Xuan Zong (Peking Union Medical College, China) aggressiveness
Hong Bae Kim (Hallym University, Korea) P155 The challenge in diagnosing endometrial stromal sarcoma
Zhyra Gail Catli (Jose B. Lingad Memorial Regional Hospital, Philippines) P144 Cytoreductive surgery and HIPEC for primary peritoneal anaplastic ependymoma with extensive peritoneal carcinomatosis Jin-Hyung Shim (Ajou University, Korea) Genetics P156 Downregulation of miR-214-3p in exosomes contributes to fibrosis P145 Cytoreductive surgery and HIPEC for intraabdominal synovial as determined by primary endometrial cell isolation from patients sarcoma with peritoneal carcinomatsois with endometriosis and by endometrial cell line culture: the role of Jin-Hyung Shim (Ajou University, Korea) exosomes in the horizontal transfer of miR-214-3p Jinwei Miao (Beijing Obstetrics and Gynecology Hospital, Capital P146 Immunohistochemical staining of PD-L1 and CD8+ T-cells in tumor Medical University, China) tissue is a useful predictor of nivolumab efficacy against mucosal melanoma P157 Effectiveness of a newly designed genetic panel containing 28 genes Kohei Omatsu (Cancer Institute Hospital, Japan) for gynecological cancers: an exploratory study Hodaka Takeuchi (Shinshu University, Japan)
60 61 P158 Reclassification of BRCA1 and BRCA2 variants of uncertain P169 Side effects among patients with invasive cervical cancer receiving significance in ovarian epithelial, fallopian tube, and primary cisplatin by age range: prospective study peritoneal cancer Rachadapan Chaitosa (Ramathibodi Hospital, Thailand) Hyeong In Ha (National Cancer Center, Korea) P170 Periumbilical infiltration of lidocaine with epinephrine vs bupivacaine P159 Nation-wide analysis of clinical NGS panel for performing precision for postoperative pain reduction in multi-port laparoscopic adnexal oncology for epithelial ovarian, peritoneal and tubal cancer patient surgery (KGOG 3047 study) ? Preliminary analysis reports of retrospective Whan Shin (Yonsei University, Korea) study Jihye Kim (Dankook University, Korea) Supportive Care
P171 Cambodian gynecological cancer patients who received treatment P160 Real-world experience of pembrolizumab in patients with at Surin province, supportive care system gynecologic malignancy: the first reports of Republic of Korea Ajaree Sethong (Surin Hospital, Thailand) Myeong Seon Kim (Sungkyunkwan University, Korea)
P172 Prevention of venous thromboembolism in gynecologic oncology P161 Correlation between homeobox gene upregulation and poor survival surgery outcomes in cervical carcinoma Chul Kwon Lim (University of Ulsan, Korea) Sung Pil Choo (Yonsei University, Korea)
P173 Men’s awareness of cervical cancer P162 Dysregulated expression of homeobox family genes may influence Hae Won Kim (Seoul National University, Korea) survival outcomes of patients with epithelial ovarian cancer: analysis
of data from the cancer genome atlas P174 Fear of receiving less effective care: a barrier to effective cancer care Sung Pil Choo (Yonsei University, Korea) cost communication Hyemin Yeo (National Cancer Center, Korea) Quality of Life
P163 Are we ready for the increasing burden of cancer care cost? A willing- Fertility Preservation to-pay analysis P175 Korean nurses' attitude toward cancer treatment during pregnancy Hyemin Yeo (National Cancer Center, Korea) Hae Won Kim (Seoul National University, Korea)
P164 Conditional relative survival of cervical cancer: analysis of Korean P176 Oncologic and reproductive outcomes of ovarian cystectomy as a central cancer registry data fertility-sparing treatment for early-stage epithelial ovarian cancer Jaeman Bae (Hanyang University, Korea) Kazuhisa Kitami (Nagoya University, Japan)
P165 Sexual dysfunction, symptomatic lymphedema and impaired global P177 Pregnancy outcome after MPA therapy QOL are common in ovarian cancer survivors Masae Yoo (Osaka Medical College, Japan) Jooyoung Kim (Seoul National University, Korea)
P178 The feasibility of gonadotropin-releasing hormone agonists for P166 Short-term benefits of balneotherapy for patients with chronic pelvic prevention of chemotherapy-induced ovarian insufficiency in pain: a pilot study in Korea patient with malignant ovarian germ cell tumors Kyung-Jin Min (Korea University, Korea) Min Chul Choi (CHA University, Korea)
P167 Sexual function in cervical cancer survivors: a multi-level meta- P179 Characteristics and therapeutic effects for progestin-resistant early analysis with qualitative comparative analysis endometrial cancer and atypical hyperplasia patients receiving Nutthaporn Chandeying (Navamindradhiraj University, Thailand) fertility-sparing treatment
Shuang Zhou (Obstetrics and Gynecology Hospital of Fudan P168 A longitudinal study of symptom experience in Ramathibodi Hospital University, China) cervical cancer patients receive chemotherapy: cisplatin
Rachadapan Chaitosa (Ramathibodi Hospital, Thailand)
62 63 P180 Does fertility-sparing treatment of endometrial cancer or atypical P191 CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell- hyperplasia patients affect their offspring on physical and behavioral cycle arrest and inhibits invasion in murine cervical cancer development? Yuyeon Jung (The Catholic University of Korea, Korea) Yiqin Wang (Peking University People's Hospital, China) Clinical trials, Trials in Progress P181 From circulating to pathological biomarkers: a dynamic study of fertility-sparing treatment of endometrial cancer and atypical P192 Mainstreaming genetic counselling for genetic testing of BRCA1 and hyperplasia BRCA2 in ovarian cancer patients in Malaysia (MaGiC Study) Yiqin Wang (Peking University People's Hospital, China) Anuradha Suberamaniam (University of Malaya Medical Centre, Malaysia)
P193 A multicenter phase I/II a study of BVAC-C in patients with multiple Translational Research metastatic progress or recurrent HPV 16 or 18 positive cervix cancer P182 Efficient tumor clearance by stimulated CD8+ T cell through after fail to standard care combination immunotherapies in cervical cancer bearing mouse Byoung Gie Kim (Sungkyunkwan University, Korea) Dae Woo Lee (The Catholic University of Korea, Korea) P194 Reduction Of cycles of neoadjuvant chemotherapy for advanced P183 Blockade of PD-L1 enhances cancer immunotherapy by regulating epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): dendritic cell maturation study protocol for a phase III randomized controlled trial Heng-Cheng Hsu (National Taiwan University Hospital Hsin-Chu Hee Seung Kim (Seoul National University, Korea) Branch, Taiwan)
P195 KEYNOTE-826: a phase 3 randomized trial of chemotherapy with and P184 BET bromodomain proteins, BRD3 and BRD4, play a crucial role in without pembrolizumab for first-line treatment of advanced cervical ovarian cancer cell survival cancer Mi-Kyung Kim (Ewha Womans University, Korea) Jae-Weon Kim (Seoul National University, Korea)
P185 Anti-cancer effect of PARP inhibitor (olaparib) with DNA- P196 A multi-center, double-blind, randomized, placebo-controlled phase demethylating agents(5-azacytidine) in ovarian cancer III clinical study evaluating niraparib as maintenance therapy in Soo Young Jeong (Samsung Medical Center, Korea) Chinese patients with platinum-sensitive, recurrent ovarian cancer
Jia Zhang (Fudan University Shanghai Cancer Center, China) P186 DDX53 confers the self-renewal and drug-resistance of ovarian
cancer stem-like cells P197 An umbrella study of biomarker-driven targeted therapy in patients Sung Taek Park (Hallym University, Korea) with platinum-resistant recurrent ovarian cancer:
Jung-Yun Lee (Yonsei University, Korea) P187 Targeting casein kinase 2 disrupts intracellular trafficking of IGF2R
and lysosomal homeostasis and induced cell death in cervical cancer Takashi Takeda (Keio University, National Cancer Center Research P198 A phase II study of neoadjuvant chemotherapy plus durvalumab Institute, Japan) (MEDI4736) and tremelimumab in advanced-stage ovarian cancer: Jung-Yun Lee (Yonsei University, Korea) P188 Increase paclitaxel sensitivity to better suppress serous epithelial ovarian cancer via ablating androgen receptor/ aryl hydrocarbon P199 Comparative effectiveness of HIPEC following interval debulking receptor-ABCG2 Axis surgery in patients with advanced-stage ovarian cancer: KGOG 3042 Yao-Ching Hung (China Medical University Hospital, Taiwan) Jung-Yun Lee (Yonsei University, Korea)
P189 Role of inhibition of fibroblast growth factors (FGFs) / fibroblast P200 A phase II trial to evaluate the efficacy of bortezomiab and pegylated growth factor receptors (FGFRs) axis in epithelial ovarian cancer liposomal doxorubicin in patients with BRCA wild type platinum- Yoo-Young Lee (Samsung Medical Center, Korea) resistant recurrent ovarian cancer: KGOG 3044, EBLIN Jung-Yun Lee (Yonsei University, Korea) P190 The notch signaling change by catecholamine in epithelial ovarian cancer Younghan Park (Hallym University, Korea)
64 65 P201 ATHENA (GOG-3020/ENGOT-ov45): a randomized, double- P210 Clinical application analysis of sentinel lymph node biopsy in cervical blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) cancer polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor Hongyi Hou (Peking University People's Hospital, China) nivolumab following frontline platinum-based chemotherapy in ovarian cancer P211 Clinical application analysis of sentinel lymph node pathologic Keiichi Fujiwara (Saitama Medical University International Medical ultrastaging in early stage cervical cancer Center, Japan) Hongyi Hou (Peking University People's Hospital, China)
P202 A phase 3 trial evaluating efficacy and safety of lenvatinib in P212 Sentinel lymph node mapping using indocyanine green in robotic combination with pembrolizumab in patients with advanced surgery for the treatment of endometrial cancer and early-staged endometrial cancer cervical cancer Keiichi Fujiwara (Saitama Medical University International Medical Seongmin Kim (Korea University, Korea) Center, Japan) P213 The silent mentor as a media preservice surgical training in P203 Randomized phase III trial of long-term low-dose metronomic UFT gynecologic oncology fellowship program maintenance therapy versus observation after chemoradiation Sigit Purbadi (University of Indonesia, Indonesia) therapy for locally advanced cervical cancer (GOTIC-002) Keiichi Fujiwara (Saitama Medical University International Medical Center, Japan)
P204 A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. A GOTIC-001/JGOG3019/GCIG Study (iPocc Trial) Shoji Nagao (Hyogo Cancer Center, Japan)
P205 ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer Soo Yeon Ihm (MSD Korea, Korea)
P206 Can neoadjuvant pd-1 blockade reduce risk of distant relapse after primary therapy for resectable, advanced gynecologic malignancies? Ting-Chang Chang (Chang Gung Memorial Hospital at Linkou, Taiwan)
Surgical Techniques P207 Single-site vs. multiport robotic staging surgery in endometrial cancer Athithan Rattanaburi (The Catholic University of Korea, Korea)
P208 Effectiveness of the bipolar vessel sealer in robot-assisted pelvic and infrarenal paraaortic lymphadenectomy Do Young Chung (Kyungpook National University, Korea)
P209 Learning curve analysis and safety of splenectomy of the single gynecologic surgeon Eun Ji Lee (Seoul National University, Korea)
66 67 MSD 광고
Tour Information
Tour Information Songdo International City It is the center city of the Free Economic Zone of Incheon and 15 international organizations. As you can expect, the cityscape is modern and beautiful. The eye-catcing architecure has created a Check the latest information on sophisticated urban sensibility. It looks like the nation’s stop-level green spaces and parks put bright colors over the city. ASGO 2019 Mobile APP!! * Travel Point : City tour finding metropolitan sense that you imagined
Shopping & Food One of the pleasures of sightseeing in Songdo International City is shopping. Large shopping malls such as Hyundai Premium Outlets, Triple Street, and NC Cube Canal Walk are popular shopping.
Hyundai Premium Outlets & Triple Street ASGO 2019
- Overview of sessions, speakers and exhibitors - Browse abstracts and presentation les - Create your personal schedule for the event, including bookmarking the sessions you are interested in
How to get there - Bus No. 6, 9, 523-1, 92 - Incheon Subway Line 1, Techno Park Station
NC Cube Canal Walk
How to get there - Bus No. 82, 6-1
72 SILVER No. Category Company Exhibition Exhibition Area D1 Roche Korea Diamond D2 Astrazeneca Semi- Exhibition is opened at Grand Ballroom C, Lobby (2F) from Thursday, SD1 Takeda Pharmaceuticals Korea Diamond October 10 to Saturday, October 12. P1 Platinum MSD G1 Shinpoong Pharm Opening Hours G2 Intuitive G3 Gold Boryung Pharme Thursday, October 10 09:00 – 18:00 G4 SAMYANG BRONZE Friday, October 11 09:00 – 18:00 G5 Roche Diagnostics Korea Saturday, October 12 09:00 – 18:00 S1 Dalimbiotech S2 CJ Healthcare S3 JW PHARMACEUTICAL S4 Silver Johnson & Johnson Medical Exhibitors S5 Bayer Korea S6 Hanmi Pharm DIAMOND S7 ckd pharm B1 Hanmihealthcare B2 Janssen Lounge KARL STORZ ENDOSCOPY KOREA B3 CO.,LTD B4 Pfizer Korea B5 baxter SEMI BRONZE B6 OLYMPUS KOREA B7 Bard Korea SEMI DIAMOND Bronze B8 DW Pharm B9 GSK B10 Pharmbio B11 Medifine B12 Queen-Spec B13 Kyowa Kirin Korea B14 Stryker Korea PLATINUM SB1 GA YOUNG MEDICAL SB2 Yungjin pharmaceutical SB3 DONGA-ST SB4 MEDEN SB5 SAMSUNG 46 SB6 Uniens 47 SB7 Philosys healthcare Semi- SB8 abnobaKOREA ADVERTISEMENT Bronze GOLD SB9 Menarini SB10 HAN KOOK PHARMED CO., LTD SB11 Teva-handok SB12 Cardinal Health SB13 SEJONG MEDICAL SB14 Medtronic SB15 MEDITECH INFRAMED 46 JGO ASGO 47 TGCS
74 75 Floor Plan
Thursday, October 10 Friday, October 11 Saturday, October 12
GBR A, B GBR A, B Room 205 GBR A Special Symposium 1 Plenary Session 2 Ovarian Cancer Roundtable Special Session 3 Plenary Session 1 Special Symposium 2 Session of Chinese Gynecologic Special Session 4 Plenary Session 3 Oncologists Education Session 6 GBR A Special Symposium 3 Welcome Reception Symposium 7 GBR A Room 206, 207 Symposium 8 GBR B Symposium 3 Education Session 3 Room 204, 205 Symposium 1 Symposium 5 Special Session 1 Symposium 2 Education Session 4 Oral 3 Poster Discussion Oral 4 Education Session 5 Room 204, 205 Film 1A GBR B PBR A, B Film 1B Shingo Fujii Medical Academy Education Session 7 Education Session 1 Symposium 4 Banquet Education Session 8 Education Session 2 Symposium 6 Special Session 2 Room 206, 207 Room 206, 207 Oral 5 Oral 1 Oral 6 Oral 2 Special Session 5 Oral 7
76